Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

XBRL 30 June 2023 filed with the SEC

September 1, 2023September 1, 2023 Alterity Therapeutics

XBRL 30 June 2023 filed with the SEC

Post navigation

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

Related Posts

Dr David Stamler’s Biotech Showcase Presentation

January 7, 2019August 16, 2022

Prana Announces RD Refund

July 17, 2013August 16, 2022

Alterity Half Year Results and Investor Webcast Notification

February 19, 2021August 16, 2022

Recent Posts

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
Alterity to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065